NS Pharma has announced that the U.S. Food and Drug Agency (FDA) has approved the initiation of a Phase II Study for NS-089/NCNP-02, an exon 44 skipping candidate for the treatment of Duchenne muscular dystrophy.

“There are currently no available antisense treatments that target Duchenne patients amenable to exon 44 skipping therapy, which is why I am excited about this program and the potential advance of effective treatments for Duchenne muscular dystrophy.”

Vamshi Rao, MD, Ann & Robert H. Lurie Children’s Hospital of Chicago

“We are pleased to announce FDA’s clearance to proceed with our Phase II clinical trial in our endeavor to help patients with Duchenne amenable to exon 44 skipping therapy.”

Takeshi Seita, Vice President, R&D at NS Pharma, Inc

The study efficacy measures will include the expression of dystrophin protein and motor function. Stay tuned as trial details will be made available through ClinicalTrials.gov and our Clinical Trial Finder Tool. Defeat Duchenne Canada will share any additional information that is provided once the trial is ready to begin enrolling.